1. Search Result
Search Result
Results for "

PGH

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

3

Biochemical Assay Reagents

4

Natural
Products

2

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0837
    Imidazole
    2 Publications Verification

    Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene

    MOFs Ser/Thr Protease Thrombopoietin Receptor Neurological Disease Inflammation/Immunology
    Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole
  • HY-N0499
    Cyanidin Chloride
    4 Publications Verification

    IdB 1027

    Prostaglandin Receptor Inflammation/Immunology
    Cyanidin Chloride (IdB 1027) is an orally active antioxidant and enzyme inhibitor. Cyanidin Chloride has IC50 values of 90 μM and 60 μM against PGHS-1 and PGHS-2, respectively. Cyanidin Chloride exhibits excellent antioxidant and anti-inflammatory activities, scavenges free radicals, inhibits lipid peroxidation, and protects DNA from cleavage. Cyanidin Chloride can be used in the research of inflammatory diseases .
    Cyanidin Chloride
  • HY-108566
    U-46619
    Maximum Cited Publications
    15 Publications Verification

    9,11-Methanoepoxy PGH2

    Prostaglandin Receptor Cardiovascular Disease
    U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation .
    U-46619
  • HY-13568

    LRCL 3794

    Cytochrome P450 COX Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen
  • HY-101438

    CI-1004

    Prostaglandin Receptor Leukotriene Receptor Inflammation/Immunology Endocrinology
    Darbufelone is a dual inhibitor of cellular PGF and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50= 0.19 μM) but is much less potent with PGHS-1 (IC50=20 μM).
    Darbufelone
  • HY-139589

    ISC-27864; GRC-27864

    PGE synthase COX Collagen Neurological Disease Inflammation/Immunology
    Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH2 to prostaglandin PGE2, thereby inhibiting inflammation-related PGE2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE2 release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC50s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .
    Zaloglanstat
  • HY-136500

    PGH2

    Endogenous Metabolite Amyloid-β Neurological Disease Inflammation/Immunology
    Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor. Prostaglandin H2 can cause vasoconstriction. Prostaglandin H2 is the common precursor of all PGs and is produced by several cells that express cyclooxygen-ases. Prostaglandin H2 can activate PGD2 receptors CRTH2 and DP via interacting directly with the receptors and/or by giving rise to PGD2 after catalytic conversion by plasma proteins. Prostaglandin H2 can induce eosinophils migration and inhibit platelet aggregation. Prostaglandin H2 can accelerate the formation of dimers and higher oligomers of amyloid β1-42. Prostaglandin H2 can be used for the researches of inflammation and neurological disease, such as Alzheimer disease .
    Prostaglandin H2
  • HY-N0499A

    Prostaglandin Receptor Inflammation/Immunology
    Cyanidin is an orally active antioxidant and enzyme inhibitor. Cyanidin has IC50 values of 90 μM and 60 μM against PGHS-1 and PGHS-2, respectively. Cyanidin exhibits excellent antioxidant and anti-inflammatory activities, scavenges free radicals, inhibits lipid peroxidation, and protects DNA from cleavage. Cyanidin can be used in the research of inflammatory diseases .
    Cyanidin
  • HY-105218A
    Ifetroban sodium
    1 Publications Verification

    BMS-180291 sodium

    Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban sodium
  • HY-105218
    Ifetroban
    1 Publications Verification

    BMS-180291

    Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban
  • HY-101813

    HR325

    Dihydroorotate Dehydrogenase DNA/RNA Synthesis Prostaglandin Receptor Inflammation/Immunology
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .
    Laflunimus
  • HY-P2931

    TPI

    Biochemical Assay Reagents Metabolic Disease Cancer
    Triosephosphate isomerase (TPI) is a biocatalyst that interconverts dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate. Triosephosphate isomerase utilises Glu167 as catalytic base, mediates proton shuttling, and stabilises a cis-enediolate intermediate via loop-6 and loop-7 closure to shield its catalytic site. Triosephosphate isomerase can be used for the research of triosephosphate isomerase deficiency .
    Triosephosphate isomerase
  • HY-113330
    12S-HHT
    1 Publications Verification

    12(S)-HHTrE

    Leukotriene Receptor Endogenous Metabolite Inflammation/Immunology
    12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H2 (PGH2) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity .
    12S-HHT
  • HY-N7833

    Biochemical Assay Reagents Others
    Heneicosapentaenoic Acid (HPA) is a 21:5 omega-3 fatty acid found in trace amounts in the green alga B. pennata and in fish oils. Its chemical composition is similar to eicosapentaenoic acid (EPA), except that a carbon is extended at the carboxy terminus, placing the first double bond at the δ6 position. HPA can be used to study the importance of double bond position in omega-3 fatty acids. It incorporates phospholipids and triacylglycerols in vivo with the same efficiency as EPA and docosahexaenoic acid, and exhibits a strong inhibitory effect on the synthesis of arachidonic acid from linoleic acid. HPA is a poor substrate for prostaglandin H synthase (PGHS) (cyclooxygenase) and 5-lipoxygenase, but retains the ability to rapidly inactivate PGHS.
    Heneicosapentaenoic acid
  • HY-101438A

    CI-1004 mesylate

    Prostaglandin Receptor Leukotriene Receptor Inflammation/Immunology Endocrinology
    Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).
    Darbufelone mesylate
  • HY-N0499R

    IdB 1027 (Standard)

    Reference Standards Prostaglandin Receptor Inflammation/Immunology
    Cyanidin Chloride (IdB 1027) (Standard) is the analytical standard of Cyanidin Chloride (IdB 1027). This product is intended for research and analytical applications. Cyanidin Chloride (IdB 1027) is an orally active antioxidant and enzyme inhibitor. Cyanidin Chloride has IC50 values of 90 μM and 60 μM against PGHS-1 and PGHS-2, respectively. Cyanidin Chloride exhibits excellent antioxidant and anti-inflammatory activities, scavenges free radicals, inhibits lipid peroxidation, and protects DNA from cleavage. Cyanidin Chloride can be used in the research of inflammatory diseases.
    Cyanidin Chloride (Standard)
  • HY-118044

    Prostaglandin Receptor Cardiovascular Disease
    I-SAP is a radioiodinated TXA2/PGH2 receptor antagonist. The bind between I-SAP and the receptors, is inhibited by the histidine modifying reagent diethyl-pyrocarbonate (DEPC) .
    I-SAP
  • HY-114564

    E5510

    Prostaglandin Receptor Cardiovascular Disease
    Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .
    Satigrel
  • HY-100297

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH2, and other prostaglandins.
    MK-447
  • HY-178214

    Ser/Thr Kinase Lipoxygenase Inflammation/Immunology
    CSBP ligand 1 (Compound 36) is a ligand of CSBP, with an IC50 of 0.08 μM for CSBP binding. CSBP ligand 1 can inhibit the production of TNF in mice treated with LPS (HY-D1056). CSBP ligand 1 has no significant inhibitory activity against PGHS-1 (IC50: 16 μM) and 5-LO (IC50: 60 μM). CSBP ligand 1 can be used in the research of inflammation-related diseases .
    CSBP ligand 1
  • HY-D0837R

    Glyoxaline (Standard); 1,3-Diaza-2,4-cyclopentadiene (Standard)

    Xanthine Oxidase Reference Standards Ser/Thr Protease Thrombopoietin Receptor Neurological Disease Inflammation/Immunology
    Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole (Standard)
  • HY-134511

    Prostaglandin Receptor Inflammation/Immunology Cancer
    15(S)-HpEPE is a product of lipoxygenase hydrolysis of unsaturated fatty acids (PUFA) and is a potential inhibitor of prostaglandin H synthase 2 (PGHS-2). 15(S)-HpEPE can downregulate the expression of PGHS-2 .
    15(S)-HpEPE
  • HY-113913

    Prostaglandin Receptor Inflammation/Immunology
    12(S)-HPEPE is a lipoxygenase product and an intermediate metabolite that leads to downregulation of PGHS-2 and has potential anti-inflammatory activity. 12(S)-HPEPE reduces interleukin 1h (IL-1h)-induced PGHS-2 expression in human lung microvascular endothelial cells .
    12(S)-HPEPE
  • HY-168766

    Prostaglandin Receptor COX Inflammation/Immunology
    O-Acetylsalicylhydroxamic acid is an acetylation inhibitor of prostaglandin H2 synthase that can suppress PGE2 synthesis in the body and block the cyclooxygenase activity of PGHS in vitro. O-Acetylsalicylhydroxamic acid requires the presence of the active site residue Ser-529 to act on human PGHS-1; the S529A mutant is resistant to the inactivation effects of this inhibitor .
    O-Acetylsalicylhydroxamic acid
  • HY-131986

    TRP Channel Neurological Disease Inflammation/Immunology
    LASSBio-1135 (Compound 3a) is an orally active TRPV1 antagonist. LASSBio-1135 is an anti-inflammatory and analgesic compound. LASSBio-1135 inhibits moderately the human PGHS-2 enzyme activity (IC50 = 18.5 μM). LASSBio-1135 reverts the Capsaicin (HY-10448)-induced thermal hyperalgesia and reduces the carrageenan-induced rat paw edem .
    LASSBio-1135
  • HY-176074

    Prostaglandin Receptor Others
    U-46619 Glycine methyl ester has a modification at the C-1 position of U-46619, which uniquely alter its binding properties to the TP receptor or any of the PGH2-metabolizing enzymes. U-46619 is a stable analog of the endoperoxide PGH2. U-46619 is also an agonist of TP receptor. U-46619 can change the shape of platelet, aggregation and contraction of vascular smooth muscle. U-46619 Glycine methyl ester can be studied in research to explore the inhibition of various enzymes in the arachidonic acid metabolic pathway. U-46619 Glycine methyl ester can also act as a lipophilic prodrug form of U-46619 that alters its distribution and pharmacokinetic properties .
    U-46619 Glycine methyl ester
  • HY-113628

    VML-530

    Leukotriene Receptor Inflammation/Immunology
    ABT-080 is an orally active inhibitor of leukotriene biosynthesis. ABT-080 simultaneously blocks the leukotriene pathways leading to the synthesis of LTB4 and LTC4, but does not inhibit PGH2 biosynthesis. ABT-080 can block bronchoconstriction and be used in the research of asthma and related inflammations
    ABT-080
  • HY-101813R

    HR325 (Standard)

    Reference Standards Dihydroorotate Dehydrogenase DNA/RNA Synthesis Prostaglandin Receptor Inflammation/Immunology
    Laflunimus (Standard) is the analytical standard of Laflunimus. This product is intended for research and analytical applications. Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .
    Laflunimus (Standard)
  • HY-W699983

    Glyoxaline-15N2; 1,3-Diaza-2,4-cyclopentadiene-15N2

    Isotope-Labeled Compounds Thrombopoietin Receptor Ser/Thr Protease Xanthine Oxidase Neurological Disease Inflammation/Immunology
    Imidazole- 15N2 (Glyoxaline- 15N2) is 15N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole-15N2
  • HY-W778179

    LRCL 3794-13C,d3

    Isotope-Labeled Compounds COX Cytochrome P450 Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen- 13C, d3 is the 13C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen-13C,d3
  • HY-13568R

    LRCL 3794 (Standard)

    Reference Standards COX Cytochrome P450 Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen (Standard) is the analytical standard of Benoxaprofen. This product is intended for research and analytical applications. Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen (Standard)
  • HY-114660

    9,11-Epoxymethano PGH1; 9,11-methane-epoxy PGF1α

    Drug Derivative Cardiovascular Disease
    9,11-methane-epoxy Prostaglandin F1α (9,11-Epoxymethano PGH1; 9,11-methane-epoxy PGF1α) is a derivative of prostaglandin H1. 9,11-methane-epoxy Prostaglandin F1α induces aggregation of isolated rabbit platelets (EC50=0.88 µM) and contraction of rabbit aortic strips (EC50=0.11 µM). 9,11-methane-epoxy Prostaglandin F1α induces contraction of isolated guinea pig tracheas (EC50 = 3.4 µM) .
    9,11-Methane-epoxy prostaglandin F1α
  • HY-101438AR

    CI-1004 mesylate (Standard)

    Prostaglandin Receptor Reference Standards Leukotriene Receptor Inflammation/Immunology Endocrinology
    Darbufelone (mesylate) (Standard) is the analytical standard of Darbufelone (mesylate) (HY-101438A). This product is intended for research and analytical applications. Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF2α and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).
    Darbufelone mesylate (Standard)
  • HY-106105

    Prostaglandin Receptor Others
    ONO 3708 is a TXA2/PGH2 receptor antagonist that can inhibit the binding properties of U46619 in unactivated intact human platelets, with an IC50 value of 38 nM .
    ONO 3708
  • HY-101700A

    Prostaglandin Receptor Cardiovascular Disease
    LCB 2853 sodium is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 sodium exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 sodium can be used for the research of cardiovascular disease, such as hypertension .
    LCB 2853 sodium
  • HY-105218AR

    BMS-180291 sodium (Standard)

    Reference Standards Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban sodium (Standard) is the analytical standard of Ifetroban sodium (HY-105218A). This product is intended for research and analytical applications. Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban sodium (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: